PKCδ Serves As a Potential Biomarker and Therapeutic Target for Microglia-Mediated Neuroinflammation in Alzheimer's Disease

Ying Du,Tiantian Guo,Yunfeng Hao,Chuan Li,Linghui Tang,Xia Li,Xiaoxiao Zhang,Lin Li,Dan Yao,Xia Xu,Huaxing Si,Jinghan Zhang,Nana Zhao,Tong Yu,Yingjun Zhao,Wei Zhang,Huaxi Xu
DOI: https://doi.org/10.1002/alz.14047
2024-01-01
Alzheimer s & Dementia
Abstract:INTRODUCTION: To investigate the role of a novel type of protein kinase C delta (PKC delta) in the neuroinflammation of Alzheimer's disease (AD). METHODS: We analyzed PKC delta and inflammatory cytokines levels in cerebrospinal fluid (CSF) of AD and normal controls, as well as their correlations. The cellular expression pattern of PKC delta and the effects of PKC delta modulation on microglia-mediated neuroinflammation were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR), western blot, RNA sequencing (RNA-seq), and immunofluorescence staining. RESULTS: PKC delta levels were increased dramatically in the CSF of AD patients and positively correlated with cytokines. PKC delta is expressed mainly in microglia in the brain. Amyloid beta (A beta) stimulation increased PKC delta expression and secretion, which led to upregulation of the nuclear factor kappa B (NF-kappa B) pathway and overproduction of proinflammatory cytokines. Downregulation or inhibition of PKC delta attenuated A beta-induced microglial responses and improved cognitive function in an AD mouse model. DISCUSSION: Our study identifies PKC delta as a potential biomarker and therapeutic target for microglia-mediated neuroinflammation in AD.
What problem does this paper attempt to address?